Whole Transcriptome Sequencing Reveals Extensive Unspliced mRNA in Metastatic Castration-Resistant Prostate Cancer

Men with metastatic prostate cancer who are treated with androgen deprivation therapies (ADT) usually relapse within 2 to 3 years with disease that is termed castration-resistant prostate cancer (CRPC). To identify the mechanism that drives these advanced tumors, paired-end RNA-sequencing (RNA-seq) was performed on a panel of CRPC bone marrow biopsy specimens. From this genome-wide approach, mutations were found in a series of genes with prostate cancer relevance, including AR, NCOR1, KDM3A, KDM4A, CHD1, SETD5, SETD7, INPP4B, RASGRP3, RASA1, TP53BP1, and CDH1, and a novel SND1:BRAF gene fusion. Among the most highly expressed transcripts were 10 noncoding RNAs (ncRNAs), including MALAT1 and PABPC1, which are involved in RNA processing. Notably, a high percentage of sequence reads mapped to introns, which were determined to be the result of incomplete splicing at canonical splice junctions. Using quantitative PCR (qPCR), a series of genes (AR, KLK2, KLK3, STEAP2, CPSF6, and CDK19) were confirmed to have a greater proportion of unspliced RNA in CRPC specimens than in normal prostate epithelium, untreated primary prostate cancer, and cultured prostate cancer cells. This inefficient coupling of transcription and mRNA splicing suggests an overall increase in transcription or defect in splicing. Implications: Inefficient splicing in advanced prostate cancer provides a selective advantage through effects on microRNA networks but may render tumors vulnerable to agents that suppress rate-limiting steps in splicing. Mol Cancer Res; 13(1); 98–106. ©2014 AACR.

[1]  A. D. den Hollander,et al.  FERM protein EPB41L5 is a novel member of the mammalian CRB-MPP5 polarity complex. , 2007, Experimental cell research.

[2]  S. Dhanasekaran,et al.  The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex , 2013, Nature Genetics.

[3]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[4]  R. Nusse,et al.  Convergence of Wnt, ß-Catenin, and Cadherin Pathways , 2004, Science.

[5]  Hiroyuki Takahashi,et al.  Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer. , 2009, The American journal of pathology.

[6]  P. Nelson,et al.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. , 2011, Cancer cell.

[7]  David J. Elliott,et al.  Alternative splicing and biological heterogeneity in prostate cancer , 2009, Nature Reviews Urology.

[8]  K. Porkka,et al.  Cloning and Characterization of a Novel Six-Transmembrane Protein STEAP2, Expressed in Normal and Malignant Prostate , 2002, Laboratory Investigation.

[9]  Aviv Regev,et al.  Corrigendum: Comparative analysis of RNA sequencing methods for degraded or low-input samples , 2013, Nature Methods.

[10]  John T. Wei,et al.  Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression , 2011, Nature Biotechnology.

[11]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[12]  Christiane Garbay,et al.  p120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling. , 2009, Biochimie.

[13]  Johan Lindberg,et al.  The mitochondrial and autosomal mutation landscapes of prostate cancer. , 2013, European urology.

[14]  R. Nusse,et al.  Convergence of Wnt, beta-catenin, and cadherin pathways. , 2004, Science.

[15]  M. Horikoshi,et al.  Novel structural and functional mode of a knot essential for RNA binding activity of the Esa1 presumed chromodomain. , 2008, Journal of molecular biology.

[16]  J. Hou,et al.  Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. , 2013, The Journal of urology.

[17]  A. Bittner,et al.  Comparison of RNA-Seq and Microarray in Transcriptome Profiling of Activated T Cells , 2014, PloS one.

[18]  Elizabeth F. Smith,et al.  Pcdp1 is a central apparatus protein that binds Ca2+-calmodulin and regulates ciliary motility , 2010, The Journal of cell biology.

[19]  B. Blencowe,et al.  The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. , 2010, Molecular cell.

[20]  K. Pienta,et al.  Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. , 2012, Cancer research.

[21]  J. Hicks,et al.  Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer. , 2012, The American journal of pathology.

[22]  Francesca Demichelis,et al.  Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.

[23]  L. Tran,et al.  Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. , 2012, Cancer research.

[24]  Y. Mori,et al.  Activation of RasGRP3 by phosphorylation of Thr-133 is required for B cell receptor-mediated Ras activation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Marx,et al.  Plakophilin-associated RNA-binding proteins in prostate cancer and their implications in tumor progression and metastasis , 2013, Virchows Archiv.

[26]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[27]  J. Manley,et al.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. , 2010, Genes & development.

[28]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[29]  C. Sette,et al.  Alternative Splicing Programs in Prostate Cancer , 2013, International journal of cell biology.

[30]  M. Shen,et al.  Molecular genetics of prostate cancer: new prospects for old challenges. , 2010, Genes & development.

[31]  Clifford A. Meyer,et al.  Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.

[32]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[33]  M. Gleave,et al.  Derivation of androgen‐independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells , 1994, International journal of cancer.

[34]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[35]  Yongjun Zhao,et al.  A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation , 2012, PloS one.

[36]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[37]  Arul M Chinnaiyan,et al.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.

[38]  Joel S Parker,et al.  Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects , 2014, Genome research.

[39]  S. Amselem,et al.  Loss-of-function mutations in LRRC6, a gene essential for proper axonemal assembly of inner and outer dynein arms, cause primary ciliary dyskinesia. , 2012, American journal of human genetics.

[40]  T. Tammela,et al.  Expression of Androgen Receptor Coregulators in Prostate Cancer , 2004, Clinical Cancer Research.